| 2025-01-06 | +73.8% | M&A | Seeking Alpha | NRx stock rallies 35% on equity purchases, clinic acquisition |
| 2025-01-06 | +73.8% | M&A | PR Newswire | HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations - PR Newswire |
| 2022-05-25 | -62.0% | legal | SEC EDGAR | NRXP 8-K: 5.02 (SEC Filing) |
| 2022-07-28 | +52.8% | legal | SEC EDGAR | NRXP 8-K: 5.02 (SEC Filing) |
| 2023-06-05 | -40.5% | legal | SEC EDGAR | NRXP 8-K: 1.01, 7.01 (SEC Filing) |
| 2024-04-30 | -36.7% | legal | SEC EDGAR | NRXP 8-K: 2.04, 8.01 (SEC Filing) |
| 2026-03-24 | +35.9% | earnings | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Q4 2025 Earnings Call Transcript |
| 2026-03-24 | +35.9% | earnings | Seeking Alpha | NRx Pharmaceuticals GAAP EPS of -$1.34, revenue of $1.23M |
| 2026-03-24 | +35.9% | legal | SEC EDGAR | NRXP 8-K: 5.02, 5.07 (SEC Filing) |
| 2026-03-24 | +35.9% | news | Stock Titan | NRx says it can fund operations through 2026 as ketamine review advances - Stock Titan |
| 2026-03-24 | +35.9% | analyst | Investing.com | NRx Pharmaceuticals stock rating reiterated at Buy by BTIG on FDA progress - Investing.com |
| 2026-03-24 | +35.9% | news | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 - GlobeNewswire |
| 2026-03-24 | +35.9% | earnings | Yahoo Finance | NRx Pharmaceuticals Q4 Earnings Call Highlights - Yahoo Finance |
| 2026-03-24 | +35.9% | news | Stock Titan | NRx Pharmaceuticals (NRXP) investors OK incentive plan and board slate - Stock Titan |
| 2026-03-24 | +35.9% | legal | Stock Titan | NRXP SEC Filings - Nrx Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan |
| 2026-03-24 | +35.9% | legal | The Globe and Mail | NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress - The Globe and Mail |
| 2026-03-24 | +35.9% | news | TipRanks | NRx Pharmaceuticals Stockholders Approve Incentive Plan Amendment - TipRanks |
| 2025-01-10 | +32.0% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2024-03-12 | -31.7% | news | PR Newswire | NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales - PR Newswire |
| 2024-02-27 | -28.8% | news | InvestorPlace | Why Is NRX Pharmaceuticals (NRXP) Stock Down 23% Today? - InvestorPlace |
| 2026-04-17 | +26.5% | news | Intellectia AI | NRXP Should I Buy - Intellectia AI |
| 2024-04-18 | -26.2% | news | PR Newswire | NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock - PR Newswire |
| 2024-04-18 | -26.2% | news | InvestorPlace | Why Is NRX Pharmaceuticals (NRXP) Stock Down 29% Today? - InvestorPlace |
| 2025-06-06 | +23.7% | news | BioSpace | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine - BioSpace |
| 2024-02-28 | +21.9% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2025-01-02 | +21.3% | M&A | Seeking Alpha | NRx Pharma unit to acquire psychiatric facility Kadima |
| 2023-06-06 | -19.3% | legal | SEC EDGAR | NRXP 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-01-22 | -18.1% | legal | SEC EDGAR | NRXP 8-K: 5.02, 8.01 (SEC Filing) |
| 2023-03-31 | -17.4% | legal | SEC EDGAR | NRXP 8-K: 2.02 and (SEC Filing) |
| 2026-04-20 | +16.5% | news | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality |
| 2026-04-20 | +16.5% | earnings | MarketBeat | NRx Pharmaceuticals' (NRXP) Buy Rating Reiterated at D. Boral Capital - MarketBeat |
| 2026-04-20 | +16.5% | news | Stock Titan | Trump order aims to speed psychedelic drug reviews as NRx readies NDA - Stock Titan |
| 2025-01-29 | -15.9% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.03, 3.02, 8.01 (SEC Filing) |
| 2021-08-19 | -15.5% | legal | SEC EDGAR | NRXP 8-K: 5.02 (SEC Filing) |
| 2021-08-20 | +14.9% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-01-21 | -14.7% | news | Seeking Alpha | NRx Pharmaceuticals regains Nasdaq compliance |
| 2025-01-21 | -14.7% | legal | PR Newswire | NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement - PR Newswire |
| 2024-04-15 | -14.6% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2026-03-23 | +14.4% | analyst | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Shareholder/Analyst Call Prepared Remarks Transcript |
| 2026-03-23 | +14.4% | earnings | Seeking Alpha | NRx Pharmaceuticals Q4 2025 Earnings Preview |
| 2026-03-23 | +14.4% | earnings | Yahoo Finance | NRx Pharmaceuticals, Inc. (NRXP) Surpasses Q4 Earnings Estimates - Yahoo Finance |
| 2022-03-09 | +14.3% | legal | SEC EDGAR | NRXP 8-K: 5.02, 8.01 (SEC Filing) |
| 2025-09-08 | +14.1% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2022-02-11 | +13.8% | legal | SEC EDGAR | NRXP 8-K: 5.02 (SEC Filing) |
| 2023-09-14 | +13.4% | legal | SEC EDGAR | NRXP 8-K: 5.02, 7.01 (SEC Filing) |
| 2026-03-25 | +13.0% | news | Yahoo Finance | NRx Pharmaceuticals (NRXP) Looks to Score Double With ANDA and NDA Filings For NRX-101 - Yahoo Finance |
| 2026-03-25 | +13.0% | news | Minichart | NRx Pharmaceuticals, Inc. 8-K Filing Details: Company Information, Stock, and Warrants Registered on NASDAQ – March 2026 - Minichart |
| 2024-11-15 | +12.9% | legal | SEC EDGAR | NRXP 8-K: 2.02, 7.01 (SEC Filing) |
| 2025-08-18 | -12.8% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.02, 7.01 (SEC Filing) |
| 2025-08-18 | -12.8% | legal | Yahoo Finance | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance |
| 2025-08-18 | -12.8% | earnings | Yahoo Finance | What To Expect From NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings - Yahoo Finance |
| 2025-08-18 | -12.8% | legal | GlobeNewswire | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second - GlobeNewswire |
| 2024-06-20 | -12.4% | legal | SEC EDGAR | NRXP 8-K: 5.02 and (SEC Filing) |
| 2025-09-02 | +12.3% | legal | Yahoo Finance | NRx Pharmaceuticals, Inc. (NRXP)’ NRX-100 Wins Expanded FDA Fast Track for Suicidal Depression - Yahoo Finance |
| 2025-09-02 | +12.3% | news | Yahoo Finance | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025 Global Passion Project with Matthew Rockefeller and Rockefeller Capital - Yahoo Finance |
| 2021-09-10 | -12.2% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2024-08-13 | -11.2% | legal | PR Newswire | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds - PR Newswire |
| 2025-09-29 | +11.2% | news | Yahoo Finance | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Re-Files Abbreviated New Drug Application (ANDA) for KETAFREE™, Preservative-Free IV Ketamine - Yahoo Finance |
| 2025-09-29 | +11.2% | news | Stock Titan | $3.35B Market by 2034: NRx Develops Toxin-Free Ketamine as US Drug Shortage Continues - Stock Titan |
| 2025-06-09 | +11.0% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-02-03 | -10.9% | legal | SEC EDGAR | NRXP 8-K: 1.01, 8.01 (SEC Filing) |
| 2021-10-21 | -10.9% | legal | SEC EDGAR | NRXP 8-K: 1.01 and 8.01 (SEC Filing) |
| 2025-09-26 | +10.8% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-01-14 | -10.5% | legal | SEC EDGAR | NRXP 8-K: 5.02 and 8.01 (SEC Filing) |
| 2024-08-14 | -10.5% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.03, 3.02, 5.03, 8.01 (SEC Filing) |
| 2026-04-13 | +10.4% | executive | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer |
| 2026-04-13 | +10.4% | expansion | Stock Titan | NRx taps ex-Indivior leader as it builds for ketamine launch - Stock Titan |
| 2022-03-18 | -10.3% | legal | SEC EDGAR | NRXP 8-K: 5.02, 8.01 (SEC Filing) |
| 2024-10-30 | +10.1% | news | Seeking Alpha | HOPE Therapeutics and NRx Pharmaceuticals to buy Florida Interventional Psychiatry Clinics |
| 2026-01-05 | -10.0% | news | Stock Titan | New clinic network combines TMS and drugs to treat severe depression and PTSD - Stock Titan |
| 2023-07-28 | +9.9% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.01 (SEC Filing) |
| 2025-01-28 | +9.8% | news | Seeking Alpha | NRx Pharmaceuticals advances relationship with Anson funds with $8.9M financing |
| 2025-01-28 | +9.8% | M&A | PR Newswire | HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition - PR Newswire |
| 2024-05-16 | +9.7% | legal | SEC EDGAR | NRXP 8-K: 2.02, 7.01, 8.01 (SEC Filing) |
| 2024-08-20 | +9.4% | legal | SEC EDGAR | NRXP 8-K: 5.02 and 8.01 (SEC Filing) |
| 2023-12-21 | +9.4% | legal | SEC EDGAR | NRXP 8-K: 8.01 (SEC Filing) |
| 2024-04-02 | -9.2% | legal | SEC EDGAR | NRXP 8-K: 2.02 and (SEC Filing) |
| 2024-08-15 | -8.9% | legal | SEC EDGAR | NRXP 8-K: 2.02 and (SEC Filing) |
| 2025-03-01 | -8.8% | news | Yahoo Finance | NRx Pharmaceuticals, Inc. (NRXP): Among the Best Psychedelic Stocks to Buy in 2025 - Yahoo Finance |
| 2023-12-29 | +8.4% | legal | SEC EDGAR | NRXP 8-K: 5.02, 5.07 (SEC Filing) |
| 2025-05-13 | +8.3% | news | Seeking Alpha | HOPE Therapeutics and NRx Pharmaceuticals to buy Kadima Institute |
| 2025-05-13 | +8.3% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-05-13 | +8.3% | M&A | Stock Titan | HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics - Stock Titan |
| 2025-05-13 | +8.3% | news | Intellectia AI | NRXP Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI |
| 2022-05-31 | +8.3% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2023-02-23 | -7.7% | legal | SEC EDGAR | NRXP 8-K: 5.02 (SEC Filing) |
| 2024-08-12 | -7.6% | legal | SEC EDGAR | NRXP 8-K: 3.01 and 8.01 (SEC Filing) |
| 2026-04-21 | -7.5% | news | ChartMill | NRXP Ownership | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill |
| 2026-03-17 | -7.5% | legal | Stock Titan | FDA review finds no issues with preservative-free ketamine, dropping additive - Stock Titan |
| 2025-08-06 | -7.5% | news | Quiver Quantitative | NRXP | NRX Pharmaceuticals, Inc. Common Institutional Ownership - Quiver Quantitative |
| 2022-06-08 | -7.5% | legal | SEC EDGAR | NRXP 8-K: 5.02, 8.01 (SEC Filing) |
| 2024-11-19 | -7.3% | earnings | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript |
| 2021-10-13 | +7.0% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-05-15 | +6.8% | earnings | Seeking Alpha | NRx Pharmaceuticals reports Q1 results |
| 2025-05-15 | +6.8% | news | PR Newswire | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire |
| 2022-11-14 | -6.8% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.02 (SEC Filing) |
| 2021-08-24 | -6.7% | legal | SEC EDGAR | NRXP 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-11-17 | -6.7% | news | Seeking Alpha | NRx Pharmaceuticals outlines rapid clinic expansion and targets 6 or more locations by year-end 2025 amid new depression treatment advances |
| 2025-11-17 | -6.7% | earnings | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Q3 2025 Earnings Call Transcript |
| 2025-11-17 | -6.7% | earnings | Seeking Alpha | NRx Pharmaceuticals reports Q3 results |
| 2025-11-17 | -6.7% | news | Yahoo Finance | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Yahoo Finance |
| 2023-09-01 | -6.5% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.02, 5.03, 7.01 (SEC Filing) |
| 2024-10-15 | -6.5% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.03, 3.02 (SEC Filing) |
| 2024-02-10 | -6.2% | news | The Globe and Mail | Nrx Pharmaceuticals Inc (NRXP-Q) Stock Price and News - The Globe and Mail |
| 2021-05-26 | -6.1% | news | Zacks Investment Research | NRx Pharmaceuticals (NRXP) - Zacks Investment Research |
| 2025-03-17 | -6.1% | earnings | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript |
| 2025-03-17 | -6.1% | earnings | Seeking Alpha | NRx Pharmaceuticals GAAP EPS of -$2.36 |
| 2025-03-17 | -6.1% | news | PR Newswire | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire |
| 2023-08-31 | -6.0% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-11-12 | +5.6% | earnings | Quiver Quantitative | NRx Pharmaceuticals to Release Q3 2025 Financial Results and Host Conference Call on November 17, 2025 - Quiver Quantitative |
| 2023-02-02 | +5.6% | legal | SEC EDGAR | NRXP 8-K: 5.07 and 8.01 (SEC Filing) |
| 2023-11-14 | -5.4% | legal | SEC EDGAR | NRXP 8-K: 2.02 and (SEC Filing) |
| 2024-10-11 | -5.4% | legal | SEC EDGAR | NRXP 8-K: 5.02, 5.07, 7.01 (SEC Filing) |
| 2025-03-31 | -5.4% | M&A | Seeking Alpha | NRx Pharmaceuticals' Hope Therapeutics to acquire Dura Medical, no terms |
| 2026-03-30 | -5.3% | expansion | GlobeNewswire | Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network |
| 2026-03-30 | -5.3% | news | Stock Titan | A phone app aims to catch depression relapse between clinic visits - Stock Titan |
| 2026-03-30 | -5.3% | expansion | GlobeNewswire | Hope Therapeutics, an NRx Pharmaceuticals Subsidiary (Nasdaq:NRXP), Announces Strategic Partnership with Emobot to Integrate its AI-Powered “Depression Thermometer” Across its Interventional Psychiatry Network - GlobeNewswire |
| 2025-01-13 | +4.9% | news | Seeking Alpha | NRx Pharmaceuticals applies to uplist to Nasdaq Global Market |
| 2024-02-14 | -4.8% | legal | SEC EDGAR | NRXP 8-K: 1.01 and (SEC Filing) |
| 2024-02-14 | -4.8% | legal | SEC EDGAR | NRXP 8-K: 1.01, 8.01 (SEC Filing) |
| 2025-08-27 | -4.8% | legal | Yahoo Finance | NRx Pharmaceuticals (NASDAQ: NRXP) Announces Expanded Access Policy for NRX-100 Following FDA Fast Track Designation - Yahoo Finance |
| 2025-06-20 | -4.5% | news | Seeking Alpha | NRx Pharmaceuticals files $150M mixed shelf offering |
| 2025-05-28 | +4.4% | legal | Yahoo Finance | IBN Coverage: NRx Pharmaceuticals (NASDAQ: NRXP) Announces $10.3M Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval - Yahoo Finance |
| 2026-04-22 | -4.3% | legal | GlobeNewswire | NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program |
| 2026-04-22 | -4.3% | news | Gotrade | NRX Pharmaceuticals, Inc. Common Stock (NRXP) Stock Price Today & Analysis - Gotrade |
| 2026-04-22 | -4.3% | legal | Stock Titan | FDA backs summer review of preservative-free ketamine amid shortages - Stock Titan |
| 2026-04-22 | -4.3% | earnings | Cổng thông tin điện tử tỉnh Lào Cai | NRXP (NRX Pharmaceuticals Inc.) posts wider than expected Q4 2025 loss even as shares rise modestly today. - Cost Advantage - Cổng thông tin điện tử tỉnh Lào Cai |
| 2025-08-19 | -4.3% | earnings | Seeking Alpha | NRx Pharmaceuticals reports Q2 results |
| 2025-08-19 | -4.3% | earnings | Yahoo Finance | NRX Pharmaceuticals Inc (NRXP) Q2 2025 Earnings Report Preview: What to Expect - Yahoo Finance |
| 2026-03-29 | -4.2% | news | Simply Wall St. | NRx Pharmaceuticals (NASDAQ:NRXP) Is In A Good Position To Deliver On Growth Plans |
| 2026-03-29 | -4.2% | earnings | simplywall.st | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Has Found A Path To Profitability - simplywall.st |
| 2026-03-28 | -4.2% | news | ACCESS Newswire | New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX) |
| 2025-11-13 | -4.0% | earnings | Yahoo Finance | NRx Pharmaceuticals (NRXP) to Report Q3 2025 Financial Results and Host Conference Call on Nov. 17 - Yahoo Finance |
| 2023-02-13 | -3.8% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2024-10-21 | -3.8% | news | Seeking Alpha | NRx started at buy by EF Hutton, cites suicide prevention focus |
| 2023-03-09 | -3.7% | legal | SEC EDGAR | NRXP 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-09-12 | +3.7% | legal | SEC EDGAR | NRXP 8-K: 2.01, 7.01 (SEC Filing) |
| 2023-08-14 | +3.6% | legal | SEC EDGAR | NRXP 8-K: 1.01 and (SEC Filing) |
| 2025-08-15 | +3.6% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-05-26 | -3.6% | news | Intellectia AI | NRXP Forecast — Price Prediction for 2026. Should I Buy NRXP? - Intellectia AI |
| 2026-03-16 | +3.6% | news | Benzinga | Why Is NRx Pharma Stock Gaining Monday? - NRX Pharmaceuticals (NASDAQ:NRXP) - Benzinga |
| 2026-01-16 | +3.5% | legal | SEC EDGAR | NRXP 8-K: 3.01, 7.01, 8.01 (SEC Filing) |
| 2026-01-16 | +3.5% | news | Stock Titan | Shareholders face Jan. 26 deadline for NRx 2025 meeting proposals - Stock Titan |
| 2025-06-23 | -3.3% | earnings | PR Newswire | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100) - PR Newswire |
| 2023-04-21 | -3.0% | legal | SEC EDGAR | NRXP 8-K: 3.01, 8.01 (SEC Filing) |
| 2024-11-14 | -2.9% | earnings | Seeking Alpha | NRx Pharmaceuticals reports Q3 results |
| 2024-11-14 | -2.9% | news | Seeking Alpha | NRx Pharmaceuticals files to sell 3.3M shares of common stock for holders |
| 2025-09-24 | +2.9% | legal | Seeking Alpha | NRx Pharmaceuticals gets FDA approval for suitability petition of Ketafree |
| 2025-09-24 | +2.9% | legal | Yahoo Finance | NRx Pharmaceuticals (NRXP) Receives FDA Approval of Suitability Petition for Preservative-Free Ketamine Product - Yahoo Finance |
| 2025-09-24 | +2.9% | legal | Quiver Quantitative | NRx Pharmaceuticals Receives FDA Approval for Suitability Petition for KETAFREE™, Enabling Re-filing of ANDA for Preservative-Free Ketamine | NRXP Stock News - Quiver Quantitative |
| 2025-04-07 | -2.7% | analyst | Quiver Quantitative | NRXP | NRX Pharmaceuticals, Inc. Common Analyst Forecasts - Quiver Quantitative |
| 2025-05-27 | -2.6% | M&A | Yahoo Finance | NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Acquires Kadima Institute to Launch $100M Psychiatry Clinic Network - Yahoo Finance |
| 2025-12-18 | +2.6% | news | Stock Titan | Biotech wipes out final $5.4M debt as it pursues depression treatments - Stock Titan |
| 2025-12-18 | +2.6% | news | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion - GlobeNewswire |
| 2025-12-18 | +2.6% | news | Quiver Quantitative | NRx Pharmaceuticals Completes Repayment of $5.4 Million Debt, Positioning Company for Growth in 2026 - Quiver Quantitative |
| 2025-12-18 | +2.6% | news | Investing News Network | NRx Pharmaceuticals announces elimination of all balance sheet debt following equity conversion - Investing News Network |
| 2025-12-18 | +2.6% | news | Investing.com | NRx Pharmaceuticals clears remaining $5.4 million debt - Investing.com |
| 2025-12-18 | +2.6% | news | The Globe and Mail | NRx Pharmaceuticals (NASDAQ: NRXP) Eliminates Balance Sheet Debt Through Anson Equity Conversion - The Globe and Mail |
| 2026-02-02 | -2.5% | legal | SEC EDGAR | NRXP 8-K: 5.02 (SEC Filing) |
| 2026-02-02 | -2.5% | executive | Investing.com | NRx Pharmaceuticals appoints Joseph M. Casper as chief operating officer - Investing.com |
| 2026-03-02 | -2.4% | news | Stock Titan | Harvard brain-stimulation leader joins NRx to target PTSD, depression - Stock Titan |
| 2024-11-18 | +2.2% | executive | Seeking Alpha | NRx Pharmaceuticals appoints Michael Abrams as CFO |
| 2023-02-24 | -2.2% | legal | SEC EDGAR | NRXP 8-K: 5.07 and 8.01 (SEC Filing) |
| 2024-03-06 | -2.1% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2026-02-17 | -2.1% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2026-02-17 | -2.1% | legal | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting - GlobeNewswire |
| 2026-02-17 | -2.1% | legal | Stock Titan | FDA outlines path for NRx to use 65,000 ketamine cases in depression drug bid - Stock Titan |
| 2026-02-17 | -2.1% | news | TipRanks | NRx Pharmaceuticals Establishes $20 Million ATM Stock Program - TipRanks |
| 2026-02-18 | +2.0% | legal | The Globe and Mail | NRx Advances NRX-100 Toward Full FDA Approval Path - The Globe and Mail |
| 2022-08-22 | +1.9% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2026-03-04 | -1.8% | analyst | Investing.com | H.C. Wainwright raises NRx Pharmaceuticals stock price target to $45 - Investing.com |
| 2025-08-20 | +1.7% | news | Seeking Alpha | NRx Pharmaceuticals outlines expanded fast track for NRX-100 and targets $750M ketamine market following balance sheet strengthening |
| 2025-08-20 | +1.7% | earnings | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Q2 2025 Earnings Call Transcript |
| 2024-10-31 | -1.6% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2025-05-21 | -1.6% | legal | SEC EDGAR | NRXP 8-K: 2.02, 7.01 (SEC Filing) |
| 2022-02-03 | +1.6% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2023-03-14 | +1.5% | legal | SEC EDGAR | NRXP 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-03-21 | -1.5% | legal | SEC EDGAR | NRXP 8-K: 2.02, 7.01 (SEC Filing) |
| 2024-06-27 | +1.5% | legal | SEC EDGAR | NRXP 8-K: 1.02 and 8.01 (SEC Filing) |
| 2025-10-23 | -1.4% | legal | SEC EDGAR | NRXP 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-04-23 | -1.4% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | NRXP (NRX Pharmaceuticals Inc.) posts wider than expected Q4 2025 loss even as shares rise modestly today. - Earnings Season - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-04-23 | -1.4% | earnings | Xã Thanh Hà | NRX Pharmaceuticals (NRXP) Sector Rotation | Q4 2025: Earnings Fall Short - Professional Trade Ideas - Xã Thanh Hà |
| 2024-05-23 | +1.4% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2024-06-28 | -1.3% | news | PR Newswire | NRx Pharmaceuticals (NASDAQ:NRXP) to Proceed with Two New Drug Applications in 2024; NRX-101 has Been Returned to the Company for Filing - PR Newswire |
| 2021-05-28 | -1.2% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.01, 3.02, 3.03, 5.01, 5.02, 5.03, 5.06 (SEC Filing) |
| 2026-01-14 | +1.2% | legal | Stock Titan | 70,000 patients' ketamine data may help FDA weigh suicide therapy - Stock Titan |
| 2026-01-14 | +1.2% | legal | Yahoo Finance | NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval - Yahoo Finance |
| 2026-01-14 | +1.2% | news | Stocktwits | Why Did NRXP Stock Surge 21% Pre-Market Today? - Stocktwits |
| 2026-01-14 | +1.2% | news | Asianet Newsable | Why Did NRXP Stock Surge 21% Pre-Market Today? - Asianet Newsable |
| 2024-02-12 | -0.9% | news | PR Newswire | NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Advance of $5 Million Milestone Payment from Partners Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd. (1975.TW) - PR Newswire |
| 2025-04-17 | -0.9% | legal | SEC EDGAR | NRXP 8-K: 8.01 and (SEC Filing) |
| 2026-01-27 | -0.9% | news | Zacks Investment Research | Should I buy NRx Pharmaceuticals (NRXP) - Zacks Investment Research |
| 2026-01-27 | -0.9% | earnings | Zacks Investment Research | What date does NRx Pharmaceuticals's (NRXP) report Earnings - Earnings Calendar & Announcement - Zacks Investment Research |
| 2026-01-27 | -0.9% | news | Yahoo Finance | New Strong Sell Stocks for January 27th - Yahoo Finance |
| 2026-04-06 | +0.8% | legal | Market Exclusive | Weekly Roundup on the Cannabis Sector & Psychedelic Sector |
| 2026-04-06 | +0.8% | legal | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application |
| 2026-04-06 | +0.8% | legal | Stock Titan | FDA flags only minor label edits for U.S.-made ketamine amid backorders - Stock Titan |
| 2026-04-06 | +0.8% | legal | GlobeNewswire | NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling - GlobeNewswire |
| 2026-04-06 | +0.8% | news | Cổng thông tin điện tử Tỉnh Sơn La | Is NRX Pharmaceuticals (NRXP) Stock in an Uptrend | Price at $2.29, Up 3.86% - Trending Entry Points - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-04-06 | +0.8% | news | Xã Vĩnh Công | Is NRX Pharmaceuticals (NRXP) Stock in an Uptrend | Price at $2.29, Up 3.86% - Trending Entry Points - Xã Vĩnh Công |
| 2022-07-15 | +0.8% | legal | SEC EDGAR | NRXP 8-K: 3.01, 5.02, 8.01 (SEC Filing) |
| 2024-03-28 | -0.8% | news | PR Newswire | NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing - PR Newswire |
| 2024-04-19 | -0.7% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.02, 8.01 (SEC Filing) |
| 2026-03-19 | -0.7% | news | Stock Titan | NRx Pharma to outline drug pipeline and clinic network progress March 24 - Stock Titan |
| 2024-03-26 | -0.7% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2026-04-15 | -0.6% | news | GlobeNewswire | NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications |
| 2026-04-15 | -0.6% | news | Stock Titan | NRx aims robot-guided PTSD treatment at troops, first responders - Stock Titan |
| 2025-05-17 | -0.5% | earnings | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Q1 2025 Earnings Call Transcript |
| 2025-04-03 | -0.5% | news | BioSpace | HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE - BioSpace |
| 2023-06-07 | -0.4% | legal | SEC EDGAR | NRXP 8-K: 1.01, 3.02, 7.01 (SEC Filing) |
| 2025-12-02 | +0.3% | legal | Seeking Alpha | NRx Pharmaceuticals, Inc. (NRXP) Discusses Regulatory Update and Development Pipeline Expansion for Preservative-Free Ketamine Formulation Transcript |
| 2025-12-02 | +0.3% | legal | Yahoo Finance | NRx Pharmaceuticals (NRXP) Announces FDA Receipt of ANDA for KETAFREE With July 2026 Review Goal Date - Yahoo Finance |
| 2025-12-02 | +0.3% | legal | Stock Titan | NRx Pharmaceuticals ANDA for KETAFREE received by FDA | NRXP Stock News - Stock Titan |
| 2025-07-12 | -0.2% | news | TradingView | NRXP Options Chain — NASDAQ:NRXP - TradingView |
| 2022-11-09 | -0.2% | legal | SEC EDGAR | NRXP 8-K: 1.01, 2.03, 8.01 (SEC Filing) |
| 2024-11-20 | -0.2% | legal | SEC EDGAR | NRXP 8-K: 1.01, 5.02 (SEC Filing) |
| 2026-01-29 | +0.0% | news | MEXC | NRXP Price Today: NRX Pharmaceuticals, Inc. Stock Price, Quote & Chart - MEXC |
| 2026-04-25 | — | news | ACCESS Newswire | New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global |
| 2026-04-24 | — | analyst | ChartMill | NRXP Forecast, Price Target & Analyst Ratings | NRX PHARMACEUTICALS INC (NASDAQ:NRXP) - ChartMill |